Tag: Prescription Drugs
Molecular Residual Disease Analysis May Predict Disease Recurrence After Lung Cancer Resection
Molecular residual disease precedes DFS events in patients receiving osimertinib, placebo; most events occur after osimertinib discontinuation or completion
Long-Term Gantenerumab May Slow Decline in Dominantly Inherited Alzheimer Disease
Hazard ratio for clinical decline in Clinical Dementia Rating-Sum of Boxes was 0.53 for those treated with gantenerumab the longest
FDA Approves Blujepa for Uncomplicated Urinary Tract Infections
Medication approved for uUTIs in women and pediatric patients aged 12 years and older
Tenecteplase Is Reasonable Alternative to Alteplase for Ischemic Stroke
No significant difference seen in terms of effectiveness or safety outcomes, including functional independence at discharge
FDA Approves Tremfya for Active Crohn Disease in Adults
Tremfya is the first and only interleukin-23 inhibitor offering both subcutaneous and intravenous induction options for Crohn disease
ACP Issues Clinical Guideline for Pharmacologic Treatment of Acute Episodic Migraine
ACP recommends adding triptan to NSAID or acetaminophen to treat moderate-to-severe acute episodic migraine
Few Nonsurgical Treatments Show Effectiveness for Low Back Pain
Review reveals nonsteroidal anti-inflammatory drugs are effective for acute pain and five treatments are effective for chronic pain
AAD: Baricitinib Efficacious for Hair Regrowth in Teens With Severe Alopecia Areata
Significantly more patients receiving baricitinib 2 mg, 4 mg had SALT score ≤20, ≤10 versus placebo at week 36
Roflumilast Cream 0.05 Percent Safe, Effective in Young Children With Eczema
Significant improvement in pruritus seen within 24 hours of first application
AAD: Maintenance of Low Eczema Activity Seen After About 80 Days Off Tapinarof
Many patients who achieved clear skin with tapinarof treatment maintained low disease activity after treatment-free interval
